4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
FDMT - 4D Molecular Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$33.00
DETAILS
HIGH:
$33.00
LOW:
$33.00
MEDIAN:
$33.00
CONSENSUS:
$33.00
UPSIDE:
283.72%
Stock News
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy
4D Molecular Therapeutics NASDAQ: FDMT executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage development for wet age-related macular degeneration and prepares to begin a Phase 3 trial in diabetic macular edema.
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on May 12, 2026, the compensation committee of the Company's board of directors granted 14 new non-executive employees 141,100 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
4D Molecular Therapeutics, Inc. (FDMT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
4D Molecular Therapeutics, Inc. (FDMT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to a loss of $0.86 per share a year ago.
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
EMERYVILLE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q1 2026 financial results, provided operational highlights and outlined expected upcoming milestones.
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in May.
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on April 14, 2026, the compensation committee of the Company's board of directors granted five new non-executive employees 67,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
4D Molecular Therapeutics (NASDAQ:FDMT) versus TransCode Therapeutics (NASDAQ:RNAZ) Head-To-Head Contrast
TransCode Therapeutics (NASDAQ: RNAZ - Get Free Report) and 4D Molecular Therapeutics (NASDAQ: FDMT - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk. Insider and Institutional Ownership 99.3% of
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. decreased its position in 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) by 55.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 296,199 shares of the company's stock after selling 367,458 shares during the period. Assenagon Asset Management
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up Following Analyst Upgrade
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report)'s stock price gapped up before the market opened on Thursday after Royal Bank Of Canada raised their price target on the stock from $32.00 to $35.00. The stock had previously closed at $8.56, but opened at $9.94. Royal Bank Of Canada currently has an outperform rating
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
4D Molecular Therapeutics, Inc. (FDMT) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of a loss of $0.53 per share. This compares to a loss of $0.9 per share a year ago.
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported full year 2025 financial results, provided operational highlights and outlined expected upcoming milestones.
4DMT to Participate in Upcoming Investor Meetings
EMERYVILLE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in March.
4D Molecular Therapeutics, Inc. (FDMT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
4D Molecular Therapeutics, Inc. (FDMT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
4D Molecular Therapeutics, Inc. (FDMT) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript
4D Molecular Therapeutics, Inc. (FDMT) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in March.
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on February 10, 2026, the compensation committee of the Company's board of directors granted nine new non-executive employees 124,200 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
Enrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of initial projections 4FRONT-1 overenrolled and expected to exceed 500 patients randomized, reflecting strong interest from investigators and patients Topline data from 4FRONT-1 expected in H1 2027 4FRONT-2 global site activation momentum continues, with enrollment completion on track for H2 2026 and topline data expected in H2 2027 EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced enrollment completion for 4FRONT-1, the first Phase 3 clinical trial evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD).
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on January 13, 2026, the compensation committee of the Company's board of directors granted four new non-executive employees 23,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, which was approved by the Company's board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
Price Targets
4D Molecular price target lowered to $33 from $38 at Goldman Sachs
$33.00
(was $9.93)
Goldman Sachs
4D Molecular price target lowered to $33 from $38 at Barclays
$33.00
(was $10.17)
Gena Wang
·
Barclays
4D Molecular Therapeutics (FDMT) PT Raised to $17 at Leerink Partners
$17.00
(was $11.50)
Mani Foroohar
·
Leerink Partners
RBC Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)
$26.00
(was $10.77)
Lisa Walter
·
RBC Capital
4D Molecular price target lowered to $6 from $8 at Morgan Stanley
$6.00
(was $5.52)
Judah Frommer
·
Morgan Stanley
BMO Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)
$40.00
(was $13.28)
Kostas Biliouris
·
BMO Capital
Chardan Capital Markets Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)
$39.00
(was $13.31)
Geulah Livshits
·
Loop Capital Markets
H.C. Wainwright Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)
$36.00
(was $13.31)
Matthew Caufield
·
H.C. Wainwright
4D Molecular Therapeutics (FDMT) PT Raised to $40 at RBC Capital
$40.00
(was $26.35)
Lisa Walter
·
RBC Capital
Barclays Starts 4D Molecular Therapeutics (FDMT) at Overweight
$45.00
(was $26.35)
Gena Wang
·
Barclays
4D Molecular Therapeutics (FDMT) PT Raised to $58 at Jefferies on multiple catalysts in 2024
$58.00
(was $31.86)
Nalin Tejavibulya
·
Jefferies
4D Molecular Therapeutics (FDMT) PT Lowered to $63 at BMO Capital, 'uncertainty remains a lingering overhang until the PhIII readout'
$63.00
(was $31.59)
Kostas Biliouris
·
BMO Capital
4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast
$70.00
(was $30.70)
Kostas Biliouris
·
BMO Capital
4D Molecular Poised For Success: FDA Discussion And Solid Position In Competitive Genetic Medicine Space, Says Analyst
$30.00
(was $18.43)
Geulah Livshits
·
Chardan Capital
HC Wainwright & Co. Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $36
$36.00
(was $22.40)
H.C. Wainwright
4D Molecular Therapeutics (FDMT) Stock: Why The Price Increased
$40.00
(was $14.66)
Josh Schimmer
·
Evercore ISI